{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T15:12:49Z","timestamp":1781104369021,"version":"3.54.1"},"reference-count":0,"publisher":"National Academy of Sciences","issue":"7","content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[1992,4]]},"abstract":"<jats:p>Of nine established murine haplotypes, mice of three types (H-2d, H-2u, and H-2q) possess major histocompatibility complex class I glycoproteins able to present an identical viral peptide for recognition and lysis by virus-specific cytotoxic T lymphocytes. Incorporation of this viral epitope into a recombinant vaccinia vaccine and administration of a single dose protects mice with these three haplotypes from an ordinarily lethal challenge of virus. Hence, a common epitope can exist. The sharing of the ability to bind such epitopes among different MHC haplotypes underscores the feasibility of developing an effective cytotoxic T-lymphocyte vaccine for outbred populations like humans.<\/jats:p>","DOI":"10.1073\/pnas.89.7.2752","type":"journal-article","created":{"date-parts":[[2006,5,31]],"date-time":"2006-05-31T08:18:54Z","timestamp":1149063534000},"page":"2752-2755","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":38,"title":["A common antiviral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination."],"prefix":"10.1073","volume":"89","author":[{"given":"M B","family":"Oldstone","sequence":"first","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Tishon","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Geckeler","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Lewicki","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J L","family":"Whitton","sequence":"additional","affiliation":[{"name":"Department of Neuropharmacology, Scripps Research Institute, La Jolla, CA 92037."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[1992,4]]},"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.89.7.2752","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T13:45:31Z","timestamp":1649857531000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.89.7.2752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,4]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1992,4]]}},"alternative-id":["10.1073\/pnas.89.7.2752"],"URL":"https:\/\/doi.org\/10.1073\/pnas.89.7.2752","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,4]]},"assertion":[{"value":"1992-04-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}